Peptic Ulcer Drugs Market - Global Forecast 2026-2032

The Peptic Ulcer Drugs Market size was estimated at USD 4.99 billion in 2025 and expected to reach USD 5.26 billion in 2026, at a CAGR of 6.39% to reach USD 7.70 billion by 2032.

Peptic ulcer drugs remain central to gastrointestinal care as clinicians manage gastric ulcers, duodenal ulcers, gastroesophageal reflux–associated mucosal injury, and ulcer complications linked to Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use. The therapeutic landscape is anchored by proton pump inhibitors, H2 receptor antagonists, antibiotics for H. pylori eradication, mucosal protective agents, antacids, and newer potassium-competitive acid blockers in select markets. Demand is shaped by the high clinical burden of acid-related disorders, aging populations, widespread analgesic use, antimicrobial resistance concerns, and the need to reduce ulcer recurrence, bleeding, and hospitalization risk. Evidence-based prescribing increasingly emphasizes correct diagnosis, test-and-treat strategies for H. pylori, appropriate acid suppression duration, and deprescribing where long-term therapy lacks a clear indication. For stakeholders across pharmaceutical development, generics, specialty formulations, hospital procurement, and retail pharmacy channels, the peptic ulcer drugs category is evolving from broad acid suppression toward precision use, resistance-aware eradication regimens, improved adherence, and safety-focused lifecycle management.

The peptic ulcer drugs landscape is undergoing significant transformation as clinical practice moves beyond symptom control toward root-cause management and risk reduction. H. pylori eradication has become a defining therapeutic priority, with guideline-based regimens increasingly influenced by local antibiotic resistance patterns and prior macrolide exposure. This has strengthened the role of bismuth-containing and non-clarithromycin-based regimens in regions where clarithromycin resistance is high. At the same time, proton pump inhibitors continue to serve as first-line acid suppression therapy for many ulcer indications, while safety discussions around long-term use have encouraged closer review of treatment duration, patient risk factors, and step-down strategies. Another shift is the growing emphasis on ulcer prevention in patients using NSAIDs, antiplatelet agents, anticoagulants, or corticosteroids, particularly among older adults and patients with prior gastrointestinal bleeding. Formulation innovation, fixed-dose combinations, improved packaging, and digital adherence support are also reshaping access and treatment persistence. These changes collectively position the market around evidence-based stewardship, patient-specific therapy, and integrated gastrointestinal risk management.

Artificial intelligence is influencing peptic ulcer drug development, prescribing, pharmacovigilance, and patient engagement. In research and development, AI-enabled analytics can help identify drug targets, predict physicochemical properties, optimize formulations, and screen compounds for acid suppression or mucosal protection potential. In clinical settings, machine learning tools are increasingly used to support risk stratification by analyzing factors such as age, medication history, comorbidities, previous ulcer complications, and laboratory findings to identify patients at elevated risk of bleeding or recurrence. AI can also strengthen H. pylori management by helping interpret resistance surveillance data and guiding regionally appropriate eradication pathways when integrated with clinical governance. In real-world evidence programs, natural language processing can extract adverse event signals, treatment discontinuation patterns, and recurrence indicators from electronic health records and claims data. Patient-facing applications may improve adherence by reminding users to complete multi-drug eradication regimens and avoid interacting medicines or ulcer-aggravating behaviors. The cumulative impact of AI is not the replacement of clinical judgment, but a more data-informed ecosystem for safer prescribing, stronger antimicrobial stewardship, and more consistent treatment completion.

Asia-Pacific remains a critical region for peptic ulcer drugs due to the substantial burden of H. pylori infection in several countries, increasing healthcare access, and high use of both prescription and over-the-counter acid suppression therapies. Japan and South Korea have mature diagnostic pathways and strong adoption of H. pylori eradication practices, while China, India, and Southeast Asian markets face a dual challenge of broad patient need and antibiotic resistance management. North America is characterized by advanced endoscopy access, strong guideline adoption, high NSAID and antithrombotic exposure among aging populations, and active attention to appropriate proton pump inhibitor use. Latin America presents persistent H. pylori-related disease burden, uneven access to diagnostics, and growing reliance on standardized eradication regimens across public and private care settings. Europe is shaped by robust clinical guidelines, antimicrobial stewardship frameworks, and broad reimbursement mechanisms, with variation across Western, Central, and Eastern Europe in diagnostic access and eradication practices. The Middle East shows rising demand linked to improving healthcare infrastructure, lifestyle-related gastrointestinal conditions, and increasing specialist access in urban centers. Africa faces the combined effects of high infectious disease burden, limited endoscopy availability in many settings, affordability constraints, and the need for practical eradication protocols adapted to local resistance and access conditions.

ASEAN countries represent a dynamic environment for peptic ulcer drugs, where expanding primary care, pharmacy access, and urban hospital networks are increasing treatment availability, while heterogeneous diagnostic capacity influences H. pylori test-and-treat implementation. The GCC benefits from well-funded healthcare systems, growing gastroenterology services, and high adoption of branded and generic acid suppression therapies, with prevention of NSAID- and antithrombotic-associated ulcers becoming increasingly relevant as noncommunicable disease management expands. The European Union provides a highly regulated and guideline-driven environment, emphasizing antimicrobial stewardship, pharmacovigilance, prescribing appropriateness, and access to quality-assured generics. BRICS countries collectively represent diverse but influential demand drivers, including large patient populations, rising domestic pharmaceutical manufacturing capability, and public health priorities around affordable eradication therapy and gastrointestinal disease management. G7 markets are distinguished by advanced clinical infrastructure, strong payer scrutiny, mature generic competition, and increasing focus on deprescribing unnecessary long-term acid suppression. NATO member countries overlap substantially with advanced European and North American systems, where hospital procurement standards, military and veteran health systems, and coordinated public health approaches support structured gastrointestinal risk management and medicine safety monitoring.

In the United States, peptic ulcer drug use is shaped by widespread availability of proton pump inhibitors, high NSAID exposure, aging demographics, and strong clinical focus on preventing upper gastrointestinal bleeding in high-risk patients. Canada follows guideline-based prescribing with emphasis on medication review, deprescribing when appropriate, and equitable access through provincial systems. Mexico and Brazil face important H. pylori-related treatment needs, with access to diagnostics, antibiotic resistance awareness, and affordability influencing regimen selection. In the United Kingdom, structured primary care pathways and national prescribing guidance support rational acid suppression, while Germany and France demonstrate strong specialist access, regulated reimbursement, and antimicrobial stewardship principles in eradication therapy. Italy and Spain combine high clinical awareness of gastric disease with efforts to manage appropriate proton pump inhibitor use in older populations. Russia presents demand linked to broad gastrointestinal disease burden and varied regional access to diagnostics and specialist care. China has a substantial patient base for ulcer and H. pylori management, with improving diagnostic capacity and growing attention to resistance-informed eradication strategies. India faces high treatment demand, broad generic availability, and the need to balance affordability with responsible antibiotic use. Japan has a highly developed ulcer care environment with established H. pylori management and significant experience with advanced acid suppression options. Australia emphasizes evidence-based prescribing, pharmacy access, and risk management for NSAID users, while South Korea benefits from high endoscopy utilization, organized gastric disease screening practices, and strong clinical recognition of H. pylori-associated ulcer risk.

Industry leaders should prioritize resistance-aware H. pylori eradication strategies, including support for local susceptibility data, clear regimen education, and adherence-enhancing packaging for multi-drug therapy. Product portfolios should balance established proton pump inhibitors and H2 receptor antagonists with differentiated formulations, fixed-dose combinations where clinically justified, and mucosal protective options for patients with complex risk profiles. Commercial and medical teams should strengthen education around appropriate acid suppression duration, ulcer prophylaxis in high-risk NSAID or antithrombotic users, and deprescribing pathways for patients without ongoing indications. Manufacturers and distributors should also improve access in underserved regions through affordable generics, reliable supply chains, and heat-stable or patient-friendly formats where relevant. Digital tools can be used to support treatment completion, adverse event reporting, and patient counseling, but should be aligned with privacy standards and clinical validation. Finally, leaders should invest in real-world evidence, pharmacovigilance, and antimicrobial stewardship partnerships to demonstrate safety, effectiveness, and responsible use across diverse healthcare systems.

This executive summary is developed using a structured secondary research approach focused on verified clinical, regulatory, and public health sources. The methodology incorporates evidence from gastroenterology guidelines, peer-reviewed medical literature, drug labels, pharmacovigilance communications, antimicrobial resistance surveillance, public health publications, and health system prescribing guidance. Analysis is organized around therapeutic classes, clinical indications, regional access patterns, H. pylori management practices, NSAID-related ulcer prevention, and medicine safety considerations. Regional, group, and country insights are synthesized through qualitative comparison of healthcare infrastructure, diagnostic availability, treatment practices, regulatory environments, and disease burden indicators. The approach intentionally avoids market sizing, market share, and forecasting, focusing instead on data-backed drivers, clinical shifts, access dynamics, and strategic implications for stakeholders operating in peptic ulcer drugs.

Peptic ulcer drugs continue to play a vital role in reducing ulcer symptoms, healing mucosal injury, eradicating H. pylori, and preventing severe complications such as bleeding and perforation. The category is increasingly defined by disciplined acid suppression, antibiotic resistance stewardship, patient-specific risk assessment, and improved adherence to combination regimens. Regional variation in H. pylori prevalence, diagnostic access, reimbursement, and healthcare infrastructure creates distinct strategic priorities across Asia-Pacific, North America, Latin America, Europe, the Middle East, and Africa. At the same time, AI, real-world evidence, and digital patient support are expanding the ability to optimize therapy and monitor safety. Stakeholders that align portfolios, education, and access strategies with guideline-based care and local resistance realities will be better positioned to support sustainable, effective, and responsible peptic ulcer treatment.